821FCEC2-41D4-48D9-8B75-D87405D075F7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.369250985545335
- age_years
- 65
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.718
- E2F_TARGETS+0.634
- INTERFERON_GAMMA_RESPONSE+0.627
- G2M_CHECKPOINT+0.522
- IL6_JAK_STAT3_SIGNALING+0.502
- DNA_REPAIR+0.500
- MYC_TARGETS_V1+0.498
- MYC_TARGETS_V2+0.450
- ALLOGRAFT_REJECTION+0.438
- NOTCH_SIGNALING+0.435
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.349
- KRAS_SIGNALING_DN-0.310
- PANCREAS_BETA_CELLS-0.277
- MYOGENESIS-0.166
- APICAL_SURFACE-0.156
- ESTROGEN_RESPONSE_EARLY-0.105
- UV_RESPONSE_DN-0.053
- SPERMATOGENESIS-0.046
- ANDROGEN_RESPONSE-0.025
- APICAL_JUNCTION-0.019
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.960 |
| 2 | AFE1F307-45A7-4155-8D51-FEBD6C92947C | — | — | 0.950 |
| 3 | FD3CFD0E-E8D9-4A57-A9F0-4FB519B7E459 | — | — | 0.945 |
| 4 | C3F0BD22-6891-44F0-B023-02FC6EDFA7EB | — | — | 0.940 |
| 5 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.939 |
| 6 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.938 |
| 7 | F42071CA-8794-4C79-8B02-8D48C70E8BA1 | — | — | 0.936 |
| 8 | B7B8F0C1-3C67-4582-AF82-A3DCD0398DEC | — | — | 0.935 |
| 9 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.935 |
| 10 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.935 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.718 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.634 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.627 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.522 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.502 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.498 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.438 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.435 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.386 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.382 | Idelalisib | — uncovered |
| COMPLEMENT | 0.364 | Inavolisib | — uncovered |
| APOPTOSIS | 0.352 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.349 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.349 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.334 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.318 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.302 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.288 | Idelalisib | — uncovered |